4 research outputs found
Studies on the Regioselective Nucleophilic Aromatic Substitution (S<sub>N</sub>Ar) Reaction of 2‑Substituted 3,5-Dichloropyrazines
Differences in regioselectivity were observed during the S<sub>N</sub>Ar reaction of amines with unsymmetrical 3,5-dichloropyrazines. This study revealed that when the 2-position of the pyrazine was occupied with an electron-withdrawing group (EWG), nucleophilic attack occurred preferentially at the 5-position. When the 2-position was substituted with an electron-donating group (EDG), nucleophilic attack occurred preferentially at the 3-position. These results are reported along with a computational rationale for the experimental observations based on the Fukui index at the reacting centers
Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2<i>H</i>)‑ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) Inhibitors
A new
enhancer of zeste homolog
2 (EZH2) inhibitor series comprising a substituted phenyl ring
joined to a dimethylpyridone moiety via an amide linkage has been
designed. A preferential amide torsion that improved the binding properties
of the compounds was identified for this series via computational
analysis. Cyclization of the amide linker resulted in a six-membered
lactam analogue, compound <b>18</b>. This transformation significantly
improved the ligand efficiency/potency of the cyclized compound relative
to its acyclic analogue. Additional optimization of the lactam-containing
EZH2 inhibitors focused on lipophilic efficiency (LipE) improvement,
which provided compound <b>31.</b> Compound <b>31</b> displayed
improved LipE and on-target potency in both biochemical and cellular
readouts relative to compound <b>18</b>. Inhibitor <b>31</b> also displayed robust in vivo antitumor growth activity and dose-dependent
de-repression of EZH2 target genes
Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2<i>H</i>)‑ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) Inhibitors
A new
enhancer of zeste homolog
2 (EZH2) inhibitor series comprising a substituted phenyl ring
joined to a dimethylpyridone moiety via an amide linkage has been
designed. A preferential amide torsion that improved the binding properties
of the compounds was identified for this series via computational
analysis. Cyclization of the amide linker resulted in a six-membered
lactam analogue, compound <b>18</b>. This transformation significantly
improved the ligand efficiency/potency of the cyclized compound relative
to its acyclic analogue. Additional optimization of the lactam-containing
EZH2 inhibitors focused on lipophilic efficiency (LipE) improvement,
which provided compound <b>31.</b> Compound <b>31</b> displayed
improved LipE and on-target potency in both biochemical and cellular
readouts relative to compound <b>18</b>. Inhibitor <b>31</b> also displayed robust in vivo antitumor growth activity and dose-dependent
de-repression of EZH2 target genes
Correction to Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2<i>H</i>)‑ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) Inhibitors
Correction to Design
and Synthesis of Pyridone-Containing
3,4-Dihydroisoquinoline-1(2<i>H</i>)‑ones as a Novel
Class of Enhancer of Zeste Homolog 2 (EZH2) Inhibitor